Wang Tao,Liu Changrong,Deng Licai,et al.Clinical efficacies of different types of β receptor blockers for infantile hemangioma[J].Journal of Clinical Pediatric Surgery,2024,(02):168-172.[doi:10.3760/cma.j.cn101785-202208021-013]
不同β受体阻滞剂治疗婴幼儿血管瘤的疗效观察
- Title:
- Clinical efficacies of different types of β receptor blockers for infantile hemangioma
- Keywords:
- Hemangioma; Propranolol; Atenolol; Treatment Outcome; Drug-Related Side Effects and Adverse Reactions; Child Development
- 摘要:
- 目的 分析不同β受体阻滞剂治疗婴幼儿血管瘤的临床疗效和并发症,观察治疗期间药物对生长发育的影响。方法 本研究为前瞻性研究,选取2017年1月至2022年5月福建医科大学附属福州儿童医院烧伤整形科采用口服β受体阻滞剂治疗的33例婴幼儿血管瘤病例作为研究对象,其中男14例,女19例。按照患儿家属意愿分为普萘洛尔组(22例)和阿替洛尔组(11例),普萘洛尔组予口服非选择性β受体阻滞剂(普萘洛尔),剂量为1.5~2 mg·kg-1·d-1。阿替洛尔组予口服选择性β受体阻滞剂(阿替洛尔),剂量为第1周0.5 mg·kg-1·d-1,之后改为1 mg·kg-1·d-1。两组均每月复查1次,观察瘤体颜色、大小、质地等变化及并发症情况;分别于用药后1个月、5~6个月、10~12个月通过彩超测量瘤体体积,并进行生长发育评估。结果 两组患儿首诊年龄、性别、部位、类型等差异无统计学意义(P>0.05)。两组患儿治疗有效率均为100%。两组用药后1个月、5~6个月、10~12个月瘤体体积缩小差异无统计学意义(P>0.05)。不良反应:普萘洛尔组有5例(5/22)出现呼吸道症状、烦躁或睡眠障碍;阿替洛尔洛尔组有2例(2/11)出现烦躁或睡眠障碍;两组均无一例严重不良反应,生长发育均未发现异常,用药后1、3、6、9个月发育商比较,差异亦无统计学意义(P>0.05)。结论 β受体阻滞剂普萘洛尔与阿替洛尔治疗婴幼儿血管瘤疗效相当,对患儿生长发育均无影响。考虑普萘洛尔对呼吸道有不良影响,阿替洛尔可作为普萘洛尔的替代药物用于治疗婴幼儿血管瘤。
- Abstract:
- Objective To observe the clinical efficacy and complications of β receptor blockers for infantile hemangioma (IH) and observe the effect on growth and development during treatment.Methods From January 2017 to may 2022,33 IH children were recruited.They were randomized into two groups of propranolol (n=22) and atenolol (n=11) according to parental wishes.No significant inter-group differences existed in age,gender,location or type (P>0.05).The former group received an oral dose of non-selective propranolol 1.5-2 mg·kg-1·d-1.And the latter group was prescribed with atenolol at 0.5 mg·kg-1·d-1 in the first week and then 1 mg·kg-1·d-1.During monthly follow-ups,the changes of clinical manifestations such as tumor color,size,texture and the complications were recorded.Color Doppler ultrasound was performed for measuring tumor volume and evaluating growth and development.Results There was nostatistically significant difference in the age,gender,Location,and type of initial diagnosis between the two groups of chidren(P＞0.05).The effective rate of both groups was 100%.No statistically significant reduction occurred in tumor volume in neither groups at Month 1,5-6 and 10-12 post-treatment (P>0.05).Adverse reactions of drug dosing occurred in propranolol group (5/22,22.7%) with respiratory symptoms,fretting or sleep disorder and atenolol group(2/11,18.2%)with fretting or sleep disorder.No other serious adverse reactions occurred.No abnormality was found in physical development of neither groups during follow-ups.The developmental quotient of two groups did not differ significantly at Month 1/3/6/9 post-dosing (P>0.05).Conclusions The efficacies and complications of propranolol and atenolol are comparable for infantile hemangioma.No significant inter-group difference exists in growth and development during treatment.Regarding the impact of respiratory tract,atenolol may replace propranolol for infantile hemangiomas.
参考文献/References:
[1] 中华医学会整形外科分会血管瘤和脉管畸形学组.血管瘤和脉管畸形的诊断及治疗指南(2019版)[J].组织工程与重建外科杂志,2019,15(5):277-317.DOI:10.3969/j.issn.1673-0364.2019.05.001.Group of Hemangioma & Vascular Deformities,Plastic Surgery Branch,Chinese Medical Association:CSSVA Guidelines for Vascular Anomalies (Edition 2019)[J].J Tissue Eng Reconstr Surg,2019,15(5):277-317.DOI:10.3969/j.issn.1673-0364.2019.05.001.
[2] 郑家伟,王绪凯,秦中平,等.口服普萘洛尔治疗婴幼儿血管瘤中国专家共识(2022版)[J].中国口腔颌面外科杂志,2022,20(4):313-319.DOI:10.19438/j.cjoms.2022.04.001.Zheng JW,Wang XK,Qin ZP,et al.Chinese Expert Consensus on Using Oral Propranolol for Infantile Hemangiomas (Edition 2022)[J].China J Oral Maxillofac Surg,2022,20(4):313-319.DOI:10.19438/j.cjoms.2022.04.001.
[3] Léauté-Labrèze C,Dumas de la Roque E,Hubiche T,et al.Propranolol for severe hemangiomas of infancy[J].N Engl J Med,2008,358(24):2649-2651.DOI:10.1056/NEJMc0708819.
[4] Rotter A,de Oliveira ZNP.Infantile hemangioma:pathogenesis and mechanisms of action of propranolol[J].J Dtsch Dermatol Ges,2017,15(12):1185-1190.DOI:10.1111/ddg.13365.
[5] Ji Y,Chen SY,Yang KY,et al.Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas:a randomized clinical trial[J].JAMA Otolaryngol Head Neck Surg,2021,147(7):599-607.DOI:10.1001/jamaoto.2021.0454.
[6] Xerfan EMS,Andersen ML,Facina AS,et al.Sleep disturbances as an adverse effect of propranolol use in children with infantile hemangioma[J].World J Pediatr,2020,16(5):537-538.DOI:10.1007/s12519-019-00335-2.
[7] Langley A,Pope E.Propranolol and central nervous system function:potential implications for paediatric patients with infantile haemangiomas[J].Br J Dermatol,2015,172(1):13-23.DOI:10.1111/bjd.13379.
[8] 邱桐,杨开颖,陈思源,等.普萘洛尔影响婴幼儿血管瘤患儿中枢神经系统功能的新进展[J].临床小儿外科杂志,2019,18(8):646-649.DOI:10.3969/j.issn.1671-6353.2019.08.006.Qiu T,Yang KY,Chen SY,et al.Potential effects of propranolol on central nervous system in children with infantile hemangioma[J].J Clin Ped Sur,2019,18(8):646-649.DOI:10.3969/j.issn.1671-6353.2019.08.006.
[9] Al-Rwebah H,Alkhodair R,Al-Khenaizan S.Propranolol-induced hyperkalemia in the management of infantile hemangioma[J].JAAD Case Rep,2020,6(4):359-361.DOI:10.1016/j.jdcr.2020.01.028.
[10] Rotter A,Samorano LP,de Oliveira Labinas GH,et al.Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol[J].Int J Dermatol,2017,56(2):190-194.DOI:10.1111/ijd.13442.
[11] Young ME,江帆,张子琛,等.投资儿童早期发展以及儿科医护工作者的作用[J].中华儿科杂志,2018,56(2):81-83.DOI:10.3760/cma.j.issn.0578-1310.2018.02.001.Young ME,Jiang F,Zhang ZC,et al.Investing in early childhood development and the role of pediatric medical workers[J].Chin J Pediatr,2018,56(2):81-83.DOI:10.3760/cma.j.issn.0578-1310.2018.02.001.
[12] Seebauer CT,Graus MS,Huang L,et al.Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma[J].J Clin Invest,2022,132(3):e151109.DOI:10.1172/JCI151109.
[13] Pandey V,Tiwari P,Imran M,et al.Adverse drug reactions following propranolol in infantile hemangioma[J].Indian Pediatr,2021,58(8):753-755.
[14] Wang Q,Xiang B,Chen SY,et al.Efficacy and safety of oral atenolol for the treatment of infantile haemangioma:a systematic review[J].Australas J Dermatol,2019,60(3):181-185.DOI:10.1111/ajd.12966.
[15] Gumina ME,Yan AC.Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas[J].Pediatr Dermatol,2019,36(4):556-557.DOI:10.1111/pde.13839.
[16] Laurens C,Abot A,Delarue A,et al.Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier[J].Front Neurosci,2019,13:33.DOI:10.3389/fnins.2019.00033.
[17] 杨浩,舒强,郭晓东.婴幼儿血管瘤的治疗进展[J].临床小儿外科杂志,2019,18(8):640-645.DOI:10.3969/j.issn.1671-6353.2019.08.005.Yang H,Shu Q,Guo XD.Recent advances in the treatment of infantile hemangiomas[J].J Clin Ped Sur,2019,18(8):640-645.DOI:10.3969/j.issn.1671-6353.2019.08.005.
[18] Hu L,Zhou BR,Huang HZ,et al.Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas[J].J Dermatol,2016,43(10):1160-1166.DOI:10.1111/1346-8138.13324.
相似文献/References:
[1]周启星,杨文,成琦,等.婴儿腮腺血管瘤22例[J].临床小儿外科杂志,2007,6(03):17.
[2]杨恩 刘铭 彭强. 血管瘤血管内皮生长因子受体KDR基因异常甲基化的研究[J].临床小儿外科杂志,2012,11(04):268.
[J].Journal of Clinical Pediatric Surgery,2012,11(02):268.
[3]李凯 董岿然 肖现民. 普萘洛尔治疗婴儿型血管瘤溃疡[J].临床小儿外科杂志,2013,12(05):381.
[4]徐仙赟 谢琼珺 黄海金. 噻吗洛尔和普萘洛尔体外调控小鼠血管瘤细胞增殖及凋亡作用的比较[J].临床小儿外科杂志,2014,13(02):117.
[5]黄文雅 肖 天 李春旺 邓 敏 金 科.血管瘤并血小板减少综合征介入栓塞治疗的效果分析[J].临床小儿外科杂志,2018,17(01):43.
Huang Wenya,Xiao Tian,Li Chunwang,et al.Interventional treatment for KasabachMerrit syndrome in children:a report of 7 cases.[J].Journal of Clinical Pediatric Surgery,2018,17(02):43.
[6]高石,赵国强,岳晓洁.儿童指端血管球瘤1例报道并文献复习[J].临床小儿外科杂志,2019,18(07):615.[doi:10.3969/j.issn.1671-6353.2019.07.019]
Gao Shi,Zhao Guoqiang,Yue Xiaojie.A case report of a fingertip glomus tumor in children and literature review[J].Journal of Clinical Pediatric Surgery,2019,18(02):615.[doi:10.3969/j.issn.1671-6353.2019.07.019]
[7]刘文英.脉管异常类疾病的分类及相关临床问题[J].临床小儿外科杂志,2019,18(08):621.[doi:10.3969/j.issn.1671-6353.2019.08.001]
Liu Wenying.Classifications and clinical managements of vascular abnormalities[J].Journal of Clinical Pediatric Surgery,2019,18(02):621.[doi:10.3969/j.issn.1671-6353.2019.08.001]
[8]王川,李亚楠,向波,等.婴幼儿血管瘤生活质量专用量表的信度与效度检验及其临床应用[J].临床小儿外科杂志,2019,18(08):635.[doi:10.3969/j.issn.1671-6353.2019.08.004]
Wang Chuan,Li Yanan,Xiang Bo,et al.Measuring reliability and validity of a Chinese mandarin version quality-of-life instrument for infantile hemangioma and its clinical application[J].Journal of Clinical Pediatric Surgery,2019,18(02):635.[doi:10.3969/j.issn.1671-6353.2019.08.004]
[9]邱桐,杨开颖,陈思源,等.普萘洛尔影响婴幼儿血管瘤患儿中枢神经系统功能的新进展[J].临床小儿外科杂志,2019,18(08):646.[doi:10.3969/j.issn.1671-6353.2019.08.006]
Qiu Tong,Yang Kaiying,Chen Siyuan,et al.Potential effects of propranolol on central nervous system in children with infantile hemangioma[J].Journal of Clinical Pediatric Surgery,2019,18(02):646.[doi:10.3969/j.issn.1671-6353.2019.08.006]
[10]树叶,黄文雅,罗勇奇,等.10例婴幼儿卡梅综合征临床特征及治疗经验总结[J].临床小儿外科杂志,2019,18(09):775.[doi:10.3969/j.issn.1671-6353.2019.09.014]
Shu Ye,Huang Wenya,Luo Yongqi,et al.Summary of clinical features and treatment protocols of 10 infants with Kasabach-Merritt syndrome[J].Journal of Clinical Pediatric Surgery,2019,18(02):775.[doi:10.3969/j.issn.1671-6353.2019.09.014]
[11]张明,彭强,刘铭.NF-κB因子在普萘洛尔治疗裸鼠血管瘤模型过程中的表达[J].临床小儿外科杂志,2019,18(08):655.[doi:10.3969/j.issn.1671-6353.2019.08.008]
Zhang Ming,Peng Qiang,Liu Ming.Expression of NF-kappa B in propranolol treatment for infantile hemangioma in nude mice model[J].Journal of Clinical Pediatric Surgery,2019,18(02):655.[doi:10.3969/j.issn.1671-6353.2019.08.008]
备注/Memo
收稿日期:2022-8-11。
基金项目:福州市卫生健康科技计划项目(2019-S-wq20)
通讯作者:林向上,Email:66887151@qq.com